Colorectal or #BowelCancer is the third most common cancer worldwide. Find out about advances in research and treatment options at the #ColorectalCancer Network meeting, co-hosted by @uclh and @Oslounivsykehus in Oxford on 30-31st March.
Register now 📅 https://t.co/CJ5H6XWOkC
We are proud to announce our Institute Director, Håvard E. G. Danielsen as keynote speaker at the Australasian Gastro-Intestinal Trials Group (AGITG) Scientific Meeting 2022. #AGITG22
We are happy to announce that Fahri Saatcioglu and his team at @UniOslo & ICGI at @oslounivsykehus have been granted funding from @Kreftforeningen. The research on unfolded protein response in cancer cells will benefit many cancer patients.
https://t.co/RqjMfkryhQ
I fjor fikk nær 4000 norske kvinner brystkreft.
Tidlig diagnostisering og store fremskritt innen behandling har ført til at overlevelsen for brystkreftpasienter har blitt mye bedre 🎀🎀
MAMMOGRAFI REDDER LIV! 🌸
Les mer om brystkreft på https://t.co/2DRju9ZWak
By leveraging a deep learning marker, 1 of 3 colorectal cancer patients with local (lymph node) metastasis may safely avoid adjuvant chemotherapy. This will greatly reduce morbidity and treatment costs. @Oslounivsykehus @OsloCancercluster @forskningsradet
We welcome all interested in AI and Healthcare to an engaging afternoon and hope you will join us at the final DoMore! conference
November 24, 2021. 13:30 - 18:00
Forskningsbygget, Radiumhopsitalet, Oslo universitetssykehus, Ullernchausseen 70. https://t.co/I0sKlQYgIl
"– DoMore! er et bunnsolid investeringscase", sier Ivar Kroghrud, partner i Norselab. Les E24s artikkel om storfondet Noreslab og teknologiinvestor Øyvind Grotmols investering i DoMore! Diagnostics nå som DoMore!-prosjektet er i sluttfasen.
https://t.co/Pe1iLgTL43
We are looking forward to working with Drs. Miangela M. Lacle and Lisa van der Schee in the Dutch T1 Colorectal Cancer Working Group to improve the quality of life and survival of people with early-stage colorectal cancer.
#ai#deeplearning#colorectalcancer#domore